Borderline Personality Disorder: An Overview

By John M. Oldham, M.D.
| July 1, 2004

Dr. Oldham is currently professor and chair of the department of psychiatry and behavioral sciences at the Medical University of South Carolina. He chaired the workgroup for the APA that developed the practice guideline for the treatment of patients with BPD.

Epidemiology and Course

Borderline personality disorder is thought to occur in 1% to 2% of the general population, although there have only been a few large-scale, population-based epidemiological studies that included BPD and utilized structured interview methodology. In a careful analysis of the limited literature on the topic, Torgersen (in press) tabulated the prevalence of BPD in eight published studies, including his own Norwegian study (Torgersen, 2000). Across all eight studies, the median prevalence for BPD in the population was 1.42%, and the mean was 1.16%. The prevalence of BPD was estimated to be 10% to 20% in psychiatric outpatient populations and 15% to 20% in psychiatric inpatient populations (Gunderson, 2001).

Extensive comorbidity has been documented for BPD with other Axis II disorders (Oldham et al., 1992), as well as with Axis I disorders (Gunderson, 2001; Skodol et al., 2002a). Prominent among Axis I/BPD patterns of comorbidity are BPD and mood disorders (Skodol et al., 1999b), anxiety disorders (Skodol et al., 1995) and substance use disorders (Grant et al., 2004; Skodol et al., 1999a). The presence of comorbidity is reported to complicate the patient's treatment response (Skodol et al., 2002a). Evidence is persuasive that patients with BPD frequently have high levels of disability (Skodol et al., 2002a) and are high treatment utilizers (Bender et al., 2001).

All personality disorders, according to DSM-IV-TR, have their onset in adolescence or early adulthood and show an enduring pattern of dysfunction that is stable and of long duration. New data, however, are challenging this view of the stability of the personality disorders over time, and this is clearly the case for BPD (Grilo and McGlanish, in press). The multisite Collaborative Longitudinal Personality Disorders Study, funded by the National Institute of Mental Health, is a naturalistic study involving careful standardized sequential assessments over time. Recent data indicate that substantial percentages of patients who met semi-structured interview-based DSM-IV diagnosis of BPD at intake did not sustain that diagnosis at 24 months post-intake. Defining remission as two consecutive months during which no more than two BPD diagnostic criteria remain present, 42% of patients with BPD had remitted; if remission is defined as showing no more than two criteria for 12 consecutive months, the BPD remission rate was 28% (Grilo et al., in press). Clearly, then, the diagnosis of BPD is more variable over time than the DSM-IV generic criterion of longitudinal stability would imply. Other studies have shown similar results (Lenzenweger, 1999; Zanarini et al., 2003).

Treatment

The evidence-based American Psychiatric Association practice guideline for the treatment of patients with BPD recommends psychotherapy as the primary treatment for BPD, combined with symptom-targeted adjunctive pharmacotherapy (Oldham et al., 2001). These recommendations were made with substantial clinical confidence, based on published randomized controlled trials of both psychotherapy and pharmacotherapy, as well as clinical consensus. The APA practice guideline does not recommend a specific type of psychotherapy, but cites two types of psychotherapy that have been demonstrated to be beneficial, using a randomized controlled design: dialectical behavior therapy (DBT) (Linehan et al., 1999, 1994, 1991) and psychodynamic psychotherapy (Bateman and Fonagy, 2001, 1999). Dialectical behavior therapy involves manual-based weekly outpatient individual psychotherapy, weekly group skills training and a number of other components (Linehan, 1993). The Bateman and Fonagy (2001) psychodynamic psychotherapy study also involved weekly individual and group sessions, in this case combined with other treatment activities in a partial hospital setting. Neither treatment is a quick fix; the DBT results were based on one year of treatment and showed reduced self-injurious behavior, greater treatment adherence and improved interviewer-rated social adjustment. The psychodynamic psychotherapy results followed 18 months of treatment and showed reduced self-injurious behavior, anxiety and depression. In both cases, follow-up studies reported maintenance of gains for at least one year (Bateman and Fonagy, 2001; Linehan, 1993). Subsequent to the publication of the APA practice guideline, there have been additional reports of controlled psychotherapy trials that also appear promising (Bohus et al., 2004; Clarkin and Levy, 2003; Linehan et al., 2002; Verheul et al., 2003).

In addition to psychotherapy, the APA practice guideline recommends symptom-targeted pharmacotherapy. In a review of the literature on pharmacotherapy for BPD, studies were categorized into randomized controlled trials, open-label trials and clinical reports (Soloff, 2000; Soloff, in press). Based on clinical judgment derived from a synthesis of the evidence, three algorithms were included in the APA guideline reflecting prominence of cognitive/perceptual symptoms, affective dysregulation symptoms or impulsive-behavioral dyscontrol symptoms (Oldham et al., 2001).

Summary

Borderline personality disorder is a disabling, complex, heterogeneous disorder characterized by variable combinations of impulsive self-injurious behavior, affective instability, cognitive/perceptual symptoms, interpersonal difficulties and other symptoms. Great strides have been made in understanding the etiologies, neurobiology and longitudinal course of BPD. An evidence-based practice guideline has been developed for the disorder, and a growing number of studies demonstrate that carefully planned and administered treatment can be effective for many patients with BPD.

Pages: 1 2

References
1. Adler G (1985), Borderline Psychopathology and Its Treatment. New York: Jason Aronson.
2. Adler G, Buie DH (1979), Aloneness and borderline psychopathology: the possible relevance of child developmental issues. Int J Psychoanal 60(1):83-96.
3. Akiskal HS (1981), Subaffective disorders: dysthymic, cyclothymic and bipolar II disorders in the "borderline" realm. Psychiatr Clin North Am 4(1):25-46.
4. Akiskal HS, Chen SE, Davis GC et al. (1985), Borderline: an adjective in search of a noun. J Clin Psychiatry 46(2):41-48.
5. Bateman A, Fonagy P (1999), Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry 156(10):1563-1569 [see comment].
6. Bateman A, Fonagy P (2001), Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. Am J Psychiatry 158(1):36-42 [see comment].
7. Bender DS, Dolan RT, Skodol AE et al. (2001), Treatment utilization by patients with personality disorders. Am J Psychiatry 158(2):295-302.
8. Bohus M, Haaf B, Simms T et al. (2004), Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: a controlled trial. Behav Res Ther 42(5):487-499.
9. Clarkin JF, Levy KN (2003), A psychodynamic treatment for severe personality disorders: issues in treatment development. Psychoanalytic Inquiry 23(2):248-267.
10. Cloninger R (in press), The genetics of personality disorders. In: Textbook of Personality Disorders, Oldham JM, Skodol AE, Bender DS, eds. Arlington, Va.: American Psychiatric Publishing, Inc.
11. Costa PT, McCrea RR (1992), The five-factor model of personality and its relevance to personality disorders. J Personal Disord 6:343-359.
12. Grant BF, Stinson FS, Dawson DA et al. (2004), Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 61(4):361-368.
13. Grilo CM, McGlashan T (in press), Course and outcome. In: Textbook of Personality Disorders, Oldham JM, Skodol AE, Bender DS, eds. Arlington, Va.: American Psychiatric Publishing, Inc.
14. Grilo CM, Shea MT, Sanislow CA et al. (in press), Two-year stability and change of schizotypal, borderline, avoidant and obsessive-compulsive personality disorders. J Consul Clin Psychol.
15. Gunderson JG (1996), The borderline patient's intolerance of aloneness: insecure attachments and therapist availability. Am J Psychiatry 153(6):752-758 [see comment].
16. Gunderson JG (2001), Borderline Personality Disorder: A Clinical Guide. Washington, D.C.: American Psychiatric Press.
17. Hansenne M, Pitchot W, Pinto E et al. (2002), 5-HT1A dysfunction in borderline personality disorder. Psychol Med 32(5):935-941.
18. Hollander E, ed. (1993), Obsessive-Compulsive-Related Disorders. Washington, D.C.: American Psychiatric Publishing, Inc.
19. Juengling FD, Schmahl C, Hesslinger B et al. (2003), Positron emission tomography in female patients with borderline personality disorder. J Psychiatr Res 37(2):109-115.
20. Kernberg OF (1975), Borderline Conditions and Pathological Narcissism. New York: Jason Aronson.
21. Klein DF, Liebowitz MR (1982), Hysteroid dysphoria. Am J Psychiatry 139(11):1520-1521 [letter].
22. Lenzenweger MF (1999), Stability and change in personality disorder features: the Longitudinal Study of Personality Disorders. Arch Gen Psychiatry 56(11):1009-1015.
23. Linehan MM (1993), Cognitive-Behavioral Treatment of Borderline Personality Disorder. New York: Guilford Press.
24. Linehan MM, Armstrong HE, Suarez A et al. (1991), Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry 48(12):1060-1064 [see comment].
25. Linehan MM, Dimeff LA, Reynolds SK et al. (2002), Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend 67(1):13-26.
26. Linehan MM, Schmidt H, Dimeff LA et al. (1999), Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict 8(4):279-292.
27. Linehan MM, Tutek DA, Heard HL, Armstrong HE (1994), Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. Am J Psychiatry 151(12):1771-1776.
28. Links PS, Heslegrave RJ (2000), Prospective studies of outcome. Understanding the mechanisms of change in patients with borderline personality disorder. Psychiatr Clin North Am 23(1):137-150.
29. Masterson JF (1972), Treatment of the Borderline Adolescent: A Developmental Approach. New York: Wiley-Interscience.
30. Masterson JF, Rinsley DB (1975), The borderline syndrome: the role of the mother in the genesis and psychic structure of the borderline personality. Int J Psychoanal 56(2):163-177.
31. New AS, Siever LJ (2002), Neurobiology and genetics of borderline personality disorder. Psychiatr Ann 32(6):329-336.
32. Oldham JM (2002), A 44-year-old woman with borderline personality disorder. JAMA 287(8):1029-1037 [see comment].
33. Oldham JM, Morris LB (1995), The New Personality Self-Portrait: Why You Think, Work, Love, and Act the Way You Do. New York: Bantam Books.
34. Oldham JM, Phillips KA, Gabbard GO et al. (2001), Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 158:(10 suppl):1-52.
35. Oldham JM, Skodol AE, Kellman HD et al. (1992), Diagnosis of DSM-III-R personality disorders by two structured interviews: patterns of comorbidity. Am J Psychiatry 149(2):213-220 [see comment].
36. Pally R (2002), The neurobiology of borderline personality disorder: the synergy of "nature and nurture." Journal of Psychiatric Practice 8(3):133-142.
37. Paris J (1999), Nature and Nurture in Psychiatry: A Predisposition-Stress Model of Mental Disorders. Washington, D.C.: American Psychiatric Press.
38. Rinne T, de Kloet ER, Wouters L et al. (2002), Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. Biol Psychiatry 52(11):1102-1112.
39. Schmahl CG, Vermetten E, Elzinga BM, Douglas Bremner J (2003), Magnetic resonance imaging of hippocampal and amygdala volume in women with childhood abuse and borderline personality disorder. Psychiatr Res 122(3):193-198.
40. Siever LJ (1996), Relationship between impulsivity and compulsivity: a synthesis. In: Impulsivity and Compulsivity, Oldham JM, Hollander E, Skodol AE, eds. Washington, D.C.: American Psychiatric Press, pp261-272.
41. Siever LJ, Davis KL (1991), A psychobiological perspective on the personality disorders. Am J Psychiatry 148(12):1647-1658.
42. Siever LJ, Torgersen S, Gunderson JG et al. (2002), The borderline diagnosis III: identifying endophenotypes for genetic studies. Biol Psychiatry 51(12):964-968 [see comment].
43. Skodol AE, Gunderson JG, McGlashan TH et al. (2002a), Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. Am J Psychiatry 159(2):276-283.
44. Skodol AE, Oldham JM, Gallaher PE (1999a), Axis II comorbidity of substance use disorders among patients referred for treatment of personality disorders. Am J Psychiatry 156(5):733-738.
45. Skodol AE, Oldham JM, Hyler SE et al. (1995), Patterns of anxiety and personality disorder comorbidity. J Psychiatr Res 29(5):361-374.
46. Skodol AE, Siever LJ, Livesley WJ et al. (2002b), The borderline diagnosis II: biology, genetics, and clinical course. Biol Psychiatry 51(12):951-963 [see comment].
47. Skodol AE, Stout RL, McGlashan TH et al. (1999b), Co-occurrence of mood and personality disorders: a report from the collaborative longitudinal personality disorders study (CLPS). Depress Anxiety 10(4):175-182.
48. Soloff PH (2000), Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am 23(1):169-192, ix.
49. Soloff PH (in press), Psychopharmacology in the PD patient. In: Textbook of Personality Disorders, Oldham JM, Skodol AE, Bender DS, eds. Arlington, Va.: American Psychiatric Publishing, Inc.
50. Torgersen S (2000), Genetics of patients with borderline personality disorder. Psychiatr Clin North Am 23(1):1-9.
51. Torgersen S (in press), Epidemiology. In: Textbook of Personality Disorders, Oldham JM, Skodol AE, Bender DS, eds. Arlington, Va.: American Psychiatric Publishing, Inc.
52. Verheul R, Van Den Bosch LM, Koeter MW et al. (2003), Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. Br J Psychiatry 182:135-140 [see comment].
53. Zanarini MC (1993), Borderline personality disorder as an impulse spectrum disorder. In: Borderline Personality Disorder: Etiology and Treatment, Paris J, ed. Washington, D.C.: American Psychiatric Publishing, Inc., pp67-86.
54. Zanarini MC, Frankenburg FR (1997), Pathways to the development of borderline personality disorder. J Personal Disord 11(1):93-104.
55. Zanarini MC, Frankenburg FR, Hennen J, Silk KR (2003), The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry 160(2):274-283.

FROM PHYSICIANS PRACTICE

Five Steps to Improving Patient Access
Judy Capko, May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.

Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins, May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.

Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD, May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.

Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz, May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.

Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD, May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.

Borderline Personality Disorder: An Overview

Join the Conversation